How have KZIA shares performed in 2024?

Kazia Therapeutics' stock was trading at $0.4395 at the beginning of 2024. Since then, KZIA stock has decreased by 21.2% and is now trading at $0.3462. View the best growth stocks for 2024 here .

Are investors shorting Kazia Therapeutics?

Kazia Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 259,500 shares, an increase of 6.9% from the March 15th total of 242,800 shares. Based on an average daily volume of 838,400 shares, the short-interest ratio is presently 0.3 days. View Kazia Therapeutics' Short Interest .

What other stocks do shareholders of Kazia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC) , Inovio Pharmaceuticals (INO) , Dynavax Technologies (DVAX) , Gilead Sciences (GILD) , Idera Pharmaceuticals (IDRA) , MEI Pharma (MEIP) , Pfizer (PFE) , Telesis Bio (TBIO) , VYNE Therapeutics (VYNE) and Allena Pharmaceuticals (ALNA) .

How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KZIA

Kazia Therapeutics (KZIA) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free KZIA Stock Alerts

$0.35

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.33
▼
$0.37
50-Day Range: $0.20
▼
$0.46
52-Week Range: $0.19
▼
$1.64

Volume: 266,501 shs
Average Volume: 772,083 shs
Market Capitalization: $5.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Kazia Therapeutics alerts:

Kazia Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.59% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.16
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.40) to ($0.33) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.31 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Kazia Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
1.59% of the outstanding shares of Kazia Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Kazia Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Kazia Therapeutics has recently increased by 6.88%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Kazia Therapeutics does not currently pay a dividend.
Dividend Growth
Kazia Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KZIA.

2.1

News and Social Media Coverage

News Sentiment
Kazia Therapeutics has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Kazia Therapeutics this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for KZIA on MarketBeat in the last 30 days.
MarketBeat Follows
6 people have added Kazia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.00% of the stock of Kazia Therapeutics is held by insiders.
Percentage Held by Institutions
Only 30.89% of the stock of Kazia Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Kazia Therapeutics are expected to grow in the coming year, from ($0.40) to ($0.33) per share.
Price to Book Value per Share Ratio
Kazia Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Kazia Therapeutics Stock (NASDAQ:KZIA)

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

KZIA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KZIA Stock News Headlines

April 16, 2024 | americanbankingnews.com

Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Increase in Short Interest

March 20, 2024 | morningstar.com

Kazia Therapeutics Ltd ADR KZIA

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 16, 2024 | finance.yahoo.com

KZIA Apr 2024 2.500 call

March 13, 2024 | prnewswire.com

Kazia announces presentation of new data at AACR Annual Meeting

February 21, 2024 | msn.com

What's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?

February 21, 2024 | finanznachrichten.de

Kazia Therapeutics Limited: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

February 21, 2024 | finance.yahoo.com

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

February 21, 2024 | prnewswire.com

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

February 19, 2024 | thestreet.com

Kazia Therapeutics Limited

February 14, 2024 | wsj.com

Kazia Therapeutics Ltd. ADR

February 13, 2024 | nasdaq.com

Viking Therapeutics, Inc. Common Stock (VKTX)

January 18, 2024 | finance.yahoo.com

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

December 15, 2023 | msn.com

Kazia Therapeutics files to sell 591,697 ADSs for holders

December 5, 2023 | finance.yahoo.com

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

December 1, 2023 | marketwatch.com

Kazia Therapeutics Shares Tumble on $2 Million Direct Offering

December 1, 2023 | markets.businessinsider.com

Kazia Therapeutics Announces Registered Direct Offering - Quick Facts

December 1, 2023 | finance.yahoo.com

Kazia Therapeutics Announces $2 Million Registered Direct Offering

November 29, 2023 | msn.com

Kazia stock jumps after proposed license deal for paxalisib outside oncology

November 29, 2023 | markets.businessinsider.com

Kazia Therapeutics Enters Non-binding LOI For Paxalisib Rights Outside Of Oncology

November 29, 2023 | marketwatch.com

Kazia Therapeutics Signs Letter of Intent for Paxalisib Development, Commercialization

November 29, 2023 | finance.yahoo.com

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

November 21, 2023 | finance.yahoo.com

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

November 20, 2023 | msn.com

Kazia Therapeutics gets deficiency notice from Nasdaq

November 18, 2023 | finance.yahoo.com

Kazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past week

November 15, 2023 | finance.yahoo.com

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

See More Headlines

Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KZIA
CUSIP: N/A
CIK: 1075880
Web: www.kaziatherapeutics.com
Phone: (129) 472-4101
Fax: 61-2-9476-0388
Employees: 2,021
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.71
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $20,000.00
Price / Sales: 270.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.50 per share
Price / Book: 0.66

Miscellaneous

Outstanding Shares: 16,340,000
Free Float: 16,178,000
Market Cap: $5.41 million
Optionable: Optionable
Beta: 2.12

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. John Edwin Friend II (Age 54)
M.D., CEO, MD & Director
Comp: $721.62k
Ms. Gabrielle Heaton BBUS (ACC)
CPA, Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer
Ms. Anna Sandham
Company Secretary

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

KZIA Stock Analysis - Frequently Asked Questions

How have KZIA shares performed in 2024?: Kazia Therapeutics' stock was trading at $0.4395 at the beginning of 2024. Since then, KZIA stock has decreased by 21.2% and is now trading at $0.3462.
View the best growth stocks for 2024 here.
Are investors shorting Kazia Therapeutics?: Kazia Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 259,500 shares, an increase of 6.9% from the March 15th total of 242,800 shares. Based on an average daily volume of 838,400 shares, the short-interest ratio is presently 0.3 days.
View Kazia Therapeutics' Short Interest.
What other stocks do shareholders of Kazia Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Pfizer (PFE), Telesis Bio (TBIO), VYNE Therapeutics (VYNE) and Allena Pharmaceuticals (ALNA).
How do I buy shares of Kazia Therapeutics?: Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KZIA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kazia Therapeutics (KZIA) Stock Price, News & Analysis

Kazia Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Kazia Therapeutics Stock (NASDAQ:KZIA)

KZIA Stock Price History

KZIA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

KZIA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™